Pearl Therapeutics has raised $65 million from current investors to enable initiation of Phase 3 trials for its PT003 glycopyrrolate (GP)/formoterol fumarate (FF) MDI for the treatment of COPD, the company says. This round of financing brings the total to $167.5 million since 2007.
Pearl CEO Chuck Bramlage said, “Through our comprehensive Phase 2 program, Pearl has characterized the dose response, minimally effective dose and optimal dose for each of PT003’s components, providing us with a strong foundation for our end-of-Phase 2 meeting with the FDA and initiation of Phase 3 trials.”
Pearl announced the completion of the Phase 2 program in October 2012 and says that studies involving more than 1,000 patients had demonstrated the superiority of PT003 to each of its components and to tiotropium.
Read the Pearl Therapeutics press release.
